Acrivon Cancer Drugs: Small Trials, Big Risks & Cash Concerns
Acrivon Therapeutics (ACRV) announces clinical trial data for experimental cancer drugs ACR-368 and ACR-2316, but significant challenges remain with limited cash runway and unproven efficacy.